PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

Alena Gros, Paul F. Robbins, Xin Yao, Yong F. Li, Simon Turcotte, Eric Tran, John R. Wunderlich, Arnold Mixon, Shawn Farid, Mark E. Dudley, Ken Ichi Hanada, Jorge R. Almeida, Sam Darko, Daniel C. Douek, James C. Yang, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the repertoire of tumor-reactive and mutation-specific CD8+ lymphocytes. The lack of biomarkers limits the ability to study these cells and develop strategies to enhance clinical efficacy and extend this therapy to other malignancies. Here, we evaluated unique phenotypic traits of CD8+ TILs and TCR β chain (TCRβ) clonotypic frequency in melanoma tumors to identify patient-specific repertoires of tumor-reactive CD8+ lymphocytes. In all 6 tumors studied, expression of the inhibitory receptors programmed cell death 1 (PD-1; also known as CD279), lymphocyte-activation gene 3 (LAG-3; also known as CD223), and T cell immunoglobulin and mucin domain 3 (TIM-3) on CD8+ TILs identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8+ lymphocytes, whereas only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137). TCRβdeep sequencing revealed oligoclonal expansion of specific TCRβ?clonotypes in CD8+PD-1+ compared with CD8+PD-1- TIL populations. Furthermore, the most highly expanded TCRβclonotypes in the CD8+ and the CD8 +PD-1+ populations recognized the autologous tumor and included clonotypes targeting mutated antigens. Thus, in addition to the well-documented negative regulatory role of PD-1 in T cells, our findings demonstrate that PD-1 expression on CD8+ TILs also accurately identifies the repertoire of clonally expanded tumor-reactive cells and reveal a dual importance of PD-1 expression in the tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)2246-2259
Number of pages14
JournalJournal of Clinical Investigation
Volume124
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Neoplasms
Lymphocytes
CD137 Antigens
Population
Programmed Cell Death 1 Receptor
Mucin-3
Melanoma
T-Lymphocytes
Tumor Microenvironment
Adoptive Transfer
Lymphocyte Activation
Biomarkers
Antigens
Mutation
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., ... Rosenberg, S. A. (2014). PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. Journal of Clinical Investigation, 124(5), 2246-2259. https://doi.org/10.1172/JCI73639

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. / Gros, Alena; Robbins, Paul F.; Yao, Xin; Li, Yong F.; Turcotte, Simon; Tran, Eric; Wunderlich, John R.; Mixon, Arnold; Farid, Shawn; Dudley, Mark E.; Hanada, Ken Ichi; Almeida, Jorge R.; Darko, Sam; Douek, Daniel C.; Yang, James C.; Rosenberg, Steven A.

In: Journal of Clinical Investigation, Vol. 124, No. 5, 2014, p. 2246-2259.

Research output: Contribution to journalArticle

Gros, A, Robbins, PF, Yao, X, Li, YF, Turcotte, S, Tran, E, Wunderlich, JR, Mixon, A, Farid, S, Dudley, ME, Hanada, KI, Almeida, JR, Darko, S, Douek, DC, Yang, JC & Rosenberg, SA 2014, 'PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors', Journal of Clinical Investigation, vol. 124, no. 5, pp. 2246-2259. https://doi.org/10.1172/JCI73639
Gros, Alena ; Robbins, Paul F. ; Yao, Xin ; Li, Yong F. ; Turcotte, Simon ; Tran, Eric ; Wunderlich, John R. ; Mixon, Arnold ; Farid, Shawn ; Dudley, Mark E. ; Hanada, Ken Ichi ; Almeida, Jorge R. ; Darko, Sam ; Douek, Daniel C. ; Yang, James C. ; Rosenberg, Steven A. / PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 5. pp. 2246-2259.
@article{836fa3328f064188b0a5da9b5e865497,
title = "PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors",
abstract = "Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the repertoire of tumor-reactive and mutation-specific CD8+ lymphocytes. The lack of biomarkers limits the ability to study these cells and develop strategies to enhance clinical efficacy and extend this therapy to other malignancies. Here, we evaluated unique phenotypic traits of CD8+ TILs and TCR β chain (TCRβ) clonotypic frequency in melanoma tumors to identify patient-specific repertoires of tumor-reactive CD8+ lymphocytes. In all 6 tumors studied, expression of the inhibitory receptors programmed cell death 1 (PD-1; also known as CD279), lymphocyte-activation gene 3 (LAG-3; also known as CD223), and T cell immunoglobulin and mucin domain 3 (TIM-3) on CD8+ TILs identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8+ lymphocytes, whereas only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137). TCRβdeep sequencing revealed oligoclonal expansion of specific TCRβ?clonotypes in CD8+PD-1+ compared with CD8+PD-1- TIL populations. Furthermore, the most highly expanded TCRβclonotypes in the CD8+ and the CD8 +PD-1+ populations recognized the autologous tumor and included clonotypes targeting mutated antigens. Thus, in addition to the well-documented negative regulatory role of PD-1 in T cells, our findings demonstrate that PD-1 expression on CD8+ TILs also accurately identifies the repertoire of clonally expanded tumor-reactive cells and reveal a dual importance of PD-1 expression in the tumor microenvironment.",
author = "Alena Gros and Robbins, {Paul F.} and Xin Yao and Li, {Yong F.} and Simon Turcotte and Eric Tran and Wunderlich, {John R.} and Arnold Mixon and Shawn Farid and Dudley, {Mark E.} and Hanada, {Ken Ichi} and Almeida, {Jorge R.} and Sam Darko and Douek, {Daniel C.} and Yang, {James C.} and Rosenberg, {Steven A.}",
year = "2014",
doi = "10.1172/JCI73639",
language = "English (US)",
volume = "124",
pages = "2246--2259",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

AU - Gros, Alena

AU - Robbins, Paul F.

AU - Yao, Xin

AU - Li, Yong F.

AU - Turcotte, Simon

AU - Tran, Eric

AU - Wunderlich, John R.

AU - Mixon, Arnold

AU - Farid, Shawn

AU - Dudley, Mark E.

AU - Hanada, Ken Ichi

AU - Almeida, Jorge R.

AU - Darko, Sam

AU - Douek, Daniel C.

AU - Yang, James C.

AU - Rosenberg, Steven A.

PY - 2014

Y1 - 2014

N2 - Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the repertoire of tumor-reactive and mutation-specific CD8+ lymphocytes. The lack of biomarkers limits the ability to study these cells and develop strategies to enhance clinical efficacy and extend this therapy to other malignancies. Here, we evaluated unique phenotypic traits of CD8+ TILs and TCR β chain (TCRβ) clonotypic frequency in melanoma tumors to identify patient-specific repertoires of tumor-reactive CD8+ lymphocytes. In all 6 tumors studied, expression of the inhibitory receptors programmed cell death 1 (PD-1; also known as CD279), lymphocyte-activation gene 3 (LAG-3; also known as CD223), and T cell immunoglobulin and mucin domain 3 (TIM-3) on CD8+ TILs identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8+ lymphocytes, whereas only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137). TCRβdeep sequencing revealed oligoclonal expansion of specific TCRβ?clonotypes in CD8+PD-1+ compared with CD8+PD-1- TIL populations. Furthermore, the most highly expanded TCRβclonotypes in the CD8+ and the CD8 +PD-1+ populations recognized the autologous tumor and included clonotypes targeting mutated antigens. Thus, in addition to the well-documented negative regulatory role of PD-1 in T cells, our findings demonstrate that PD-1 expression on CD8+ TILs also accurately identifies the repertoire of clonally expanded tumor-reactive cells and reveal a dual importance of PD-1 expression in the tumor microenvironment.

AB - Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the repertoire of tumor-reactive and mutation-specific CD8+ lymphocytes. The lack of biomarkers limits the ability to study these cells and develop strategies to enhance clinical efficacy and extend this therapy to other malignancies. Here, we evaluated unique phenotypic traits of CD8+ TILs and TCR β chain (TCRβ) clonotypic frequency in melanoma tumors to identify patient-specific repertoires of tumor-reactive CD8+ lymphocytes. In all 6 tumors studied, expression of the inhibitory receptors programmed cell death 1 (PD-1; also known as CD279), lymphocyte-activation gene 3 (LAG-3; also known as CD223), and T cell immunoglobulin and mucin domain 3 (TIM-3) on CD8+ TILs identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8+ lymphocytes, whereas only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137). TCRβdeep sequencing revealed oligoclonal expansion of specific TCRβ?clonotypes in CD8+PD-1+ compared with CD8+PD-1- TIL populations. Furthermore, the most highly expanded TCRβclonotypes in the CD8+ and the CD8 +PD-1+ populations recognized the autologous tumor and included clonotypes targeting mutated antigens. Thus, in addition to the well-documented negative regulatory role of PD-1 in T cells, our findings demonstrate that PD-1 expression on CD8+ TILs also accurately identifies the repertoire of clonally expanded tumor-reactive cells and reveal a dual importance of PD-1 expression in the tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=84899748384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899748384&partnerID=8YFLogxK

U2 - 10.1172/JCI73639

DO - 10.1172/JCI73639

M3 - Article

VL - 124

SP - 2246

EP - 2259

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -